Publications

Publications

  1. Evans SR, Follmann D. Fundamentals and Innovation in Antibiotic Trials. Statistics in Biopharmaceutical Research, 2015.
  2. Evans SR, Rubin D, Follmann D, Pennello G, Huskins WC, Powers JH, Schoenfeld D, Chuang-Stein C, Cosgrove SE, Fowler Jr. VG, Lautenbach E, Chambers HF. Desirability of Outcome Ranking (DOOR) and Response Adjusted for Duration of Antibiotic Risk (RADAR). CID, 2015.
  3. Evans SR, Hujer AM, Jiang H, Hujer KM, Hall T, Marzan C, Jacobs MR, Sampath R, Ecker DJ, Manca C, Chavda K, Zhang P, Fernandez H, Chen L, Mediavilla JR, Hill CB, Perez F, Caliendo A, Fowler Jr. VG, Chambers HF, Kreiswirth BN, and Bonomo RA. Rapid Molecular Diagnostics, Antibiotic Treatment Decisions, and Developing Approaches to Inform Empiric Therapy: PRIMERS I and II. CID, 2015.
  4. Uno H, Wittes J, Fu H, Solomon SD, Claggett B, Tian L, Cai T, Pfeffer MA, Evans SR, Wei LJ. Alternatives to hazard ratios for comparing efficacy or safety of therapies in noninferiority studies. Annals of Internal Medicine, 2015.
  5. Asakura K, Hamasaki T, Sugimoto T, Hayashi K, Evans SR, Sozu T. Sample size determination in group-sequential clinical trials with two co-primary endpoints. Statistics in Medicine, 2015.
  6. Ando Y, Hamasaki T, Evans SR, Asakura K, Sugimoto T, Sozu T, Ohno Y. Sample size considerations in clinical trials when comparing two interventions using multiple co-primary binary relative risk contrasts. Statistics in Biopharmaceutical Research, 2015.
  7. Hamasaki T, Asakura K, Evans SR, Sugimoto T, Suzo T. Group-sequential Strategies in Clinical Trials with Multiple Co-primary Outcomes. Statistics in Biopharmaceutical Research, 2015.
  8. Ochiai T, Hamasaki T, Evans SR, Asakura K, Ohno Y. Group-sequential three-arm noninferiority clinical trial designs. Statistics in Biopharmaceutical Research, 2015.
  9. Chambers HF, Bartlett JG, Bonomo RA, Cosgrove S, Cross H, Daum RS, Evans SR, Kreiswirth B, Lautenbach E, Patel R, Pettigrew MM, Rodvold K, Spellberg B, Fowler VG. Antibacterial Resistance Leadership Group: Open for Business. CID, 2014.
  10. Sugimoto T, Sozu T, Hamasaki T, Evans SR. A logrank test-based method for sizing clinical trials with two co-primary time-to- events endpoints.Biostatistics, 2013.
  11. Hamasaki T, Evans SR. Noninferiority Clinical Trials: Issues in Design, Monitoring, Analyses, and Reporting. Igaku no Ayumi (Japanese), 2013.
  12. Hamasaki T, Sugimoto T, Evans SR, Sozu T. Sample size determination for clinical trials with co-primary outcomes: Exponential event-times. Pharmaceutical Statistics, 2012.
  13. Evans SR, Ellis RJ, Chen H, Ye, Yeh TM, Lee AJ, Schifitto G, Wu K, Bosch RJ, McArthur JC, Simpson DM, Clifford DB. Peripheral Neuropathy in HIV: Prevalence and Risk Factors. AIDS, 2011.
  14. Evans SR. Fundamentals of Clinical Trial Design. Journal of Experimental Stroke & Translational Medicine, 2010.
  15. Evans SR. Clinical Trial Structures. Journal of Experimental Stroke & Translational Medicine, 2010.
  16. Evans SR. Common Statistical Concerns in Clinical Trials. Journal of Experimental Stroke & Translational Medicine, 2010.
  17. Evans SR. Estudos Clinicos de Nao-Inferioridade. Revista Brasileira de Medicina, 2010.
  18. Evans SR. Noninferiority Clinical Trials. Chance, 22:3:53-58, 2009.
  19. Li L, Evans SR, Uno H, Wei LJ. Predicted Interval Plots: A Graphical Tool for Data Monitoring in Clinical Trials. Statistics in Biopharmaceutical Research, 1:4:348-355, 2009.
  20. Evans SR, Clifford DB, Kitch DW, Goodkin D, Schifitto G, McArthur JC, Simpson DM. Simplification of the Research Diagnosis of HIV-Associated Peripheral Neuropathy. HIV Clinical Trials, 9:6:434-438, 2008.
  21. Evans SR, Li L, Wei LJ. Data Monitoring in Clinical Trials Using Prediction. Drug Information Journal, 41:733-742, 2007.
  22. Evans SR, Fichtenbaum C, Aberg J. Comparison of Direct and Indirect Measurement of LDL in HIV Infected Individuals: ACTG 5087. HIV Clinical Trials, 8:1:45-52, 2007.
  23. Evans SR. When and How Can Endpoints Be Changed after Initiation of a Randomized Clinical Trial? Public Library of Science (PLoS) Clinical Trials 2(4): e18. doi:10.1371/journal.pctr.0020018, 2007.
  24. Evans SR, Simpson D, Kitch DW, King A, Clifford DB, Cohen BA, McArthur JC. A Randomized Trial Evaluating Prosaptideâ„¢ for HIV-Associated Sensory Neuropathies: Use of an Electronic Diary to Record Neuropathic Pain. PLoS ONE, 2(7): e551. doi:10.1371/journal.pone.0000551, 2007.
  25. Evans SR, Wang R, Haija R, Zhang J, Rajicic N, Xanthakis V, Peeples L, Anderson J, Sinha S. Evaluation of Distance Learning in an Introduction to Biostatistics Course. Statistical Education Research Journal, 6(2):59-77, 2007.
  26. Evans SR, Li L. A Comparison of Goodness of Fit Tests for the Logistic GEE Model. Statistics in Medicine, 24:1245-1261, 2005.
  27. Evans SR, Hosmer DW. Goodness of Fit Tests for Mixed Effects Logistic Models. Communications in Statistics: Theory and Methods, 33:5:1139-1155, 2004.
  28. Evans SR, Hosmer DW. Goodness of Fit Tests for Logistic GEE Models: Simulation Results. Communications in Statistics: Simulation and Computation, 33:1:247-258, 2004.
  29. Evans SR, Testa MA, Cooley TP, Krown SE, Paredes J, Von Roenn JH. A Phase II Evaluation of Low-Dose Oral Etoposide for the Treatment of Relapsed or Progressed AIDS-Related Kaposi’s Sarcoma: An ACTG Clinical Study. Journal of Clinical Oncology, 20:15:3236-3241, 2002.